

Supporting Information for "Nanoformulation-by-design: An experimental and molecular dynamics study for polymer coated drug nanoparticles."

Contents

Table of Figures.....	2
Molecular Dynamics Section	5
Topologies and parameters for MD.....	5
Acetone	5
Polymer residual topologies	7
Control Simulation: mPEG350-PCL2000 in acetone	12
Control Simulation: mPEG350-PCL2000 in water	12
Control Simulation: Indomethacin NP in acetone	13
Control Simulation: Indomethacin NP in water	13
Control Simulation: Formation of polymeric NP in interfacial deposition	14
Control Simulation: Indomethacin NP in interfacial deposition	15
Main Simulation: Interfacial Deposition of mPEG350-PCL2000.....	16
Experimental Section	18
Polymer Characterisation: NMR.....	18
Polymer Characterisation: GPC	19
Polymer Characterisation: ATR-IR	23
Polymer Characterisation: DSC	23
Polymer Characterisation: Contact Angle.....	25
Polymer Characterisation: DSC	25
Polymeric NP Characterisation: DLS.....	27
Polymeric NP Characterisation: ζ -potential.....	27
Polymeric NP Characterisation TEM.....	28
Indomethacin bulk characterisation: DSC	29
Indomethacin NP Characterisation: DLS	29
Indomethacin NP Characterisation: POM.....	30
Polymer-coated indomethacin NP Characterisation: DLS	31
Polymer-coated indomethacin NP Characterisation: POM	33
Polymer-coated indomethacin NP Characterisation: TEM.....	34
Polymer-coated indomethacin NP Characterisation: Reproducibility	34
Polymer-coated indomethacin NP Characterisation: Stability	35
Polymer-coated indomethacin NP Characterisation: Effect of Drug amount... ..	35
Polymer-coated indomethacin NP Characterisation: Drug Loading	36

Table of Figures

SI Figure 1: Five mPEG350-PCL2000 polymer chains surrounded by acetone (not shown), a favourable solvent. Periodic boundary conditions (PBC) apply, where the molecules can move across the end of the box.	12
SI Figure 2: Five mPEG350-PCL2000 polymer chains surrounded by water (not shown). The polymers self aggregate within 4ns and then they form a larger polymeric NP within the first 32 ns of the simulation. PBC apply.....	12
SI Figure 3: A 5nm diameter indomethacin NP surrounded by acetone (not shown), a favourable solvent. The NP dissolves. PBC apply.....	13
SI Figure 4: A 5nm diameter indomethacin NP surrounded by water (not shown). The NP stays intact. PBC apply.	13
SI Figure 5: mPEG350 (light blue)-b-PCL2000 (dark blue) polymer chains in the phase 1 of the interfacial deposition simulation, for the formation of a polymer NP. Snapshots taken at every 20 ns, solvents not shown for clarity. The polymer chains start to aggregate,	14
SI Figure 6: mPEG350 (light blue)-b-PCL2000 (dark blue) polymer chains in the phase 2 of the interfacial deposition simulation, for the formation of a polymer NP. Snapshots taken at the end of every 10 ns MD run where acetone molecules (pink) are replaced by water molecules.	14
SI Figure 7: Control simulation of the indomethacin NP (grey) to evaluate the NP's stability in the biphasic system. The drug NP stays intact until 70 ns, however as the presence acetone (pink) in the NP's surrounding environment increases, the NP starts to swell up.	15
SI Figure 8: Phase 1 of the interfacial deposition simulation of mPEG350 (light blue)-b-PCL2000 (dark blue) polymer chains in the presence of a 5 nm indomethacin NP (grey). Solvent molecules are not shown for clarity. PBC apply. Snapshots taken at various time points of the simulation. The polymer chains start to aggregate slowly as the acetone diffuses towards the water region. The indomethacin NP stays intact in the aqueous region until it reaches close proximity with the polymer chains and gets dissolved at 108 ns. .	16
SI Figure 9: Phase 2 of the interfacial deposition for the formation of a polymer-coated drug NP. Snapshots taken at the end of every 10 ns MD run where acetone molecules (pink) are replaced by water molecules, mimicking evaporation of the acetone. A polymer-drug NP of 7nm in diameter is formed. Water is not shown for clarity, PBC conditions apply.	16
SI Figure 10: Number of contacts and the distance between the PCL blocks and the indomethacin molecules during phase 1 of the interfacial deposition.....	17
SI Figure 11: Radius of gyration (a, c) and end-to-end distances (b, d) for both phases 1 and 2 of the polymer-drug NP formation simulation. c and d refer just to phase 2.	17
SI Figure 12: NMR Spectra of the synthesised polymers. PEG350PCL: ¹ H NMR (figure 4.1) (400 MHz, CDCl ₃ , ppm): 1.41 (m,34, CH ₂ CH ₂ CH ₂), 1.68 (m, 68, CH ₂ CH ₂ CH ₂), 2.33 (t,	

34, COCH ₂), 3.40 (s,3, PEGCH ₃), 3.67 (m, 24, OCH ₂ CH ₂ O), 4.08 (t, 34, CH ₂ CH ₂ CH ₂ O), 4.25 (t,2, CH ₂ CH ₂ OCO).	18
SI Figure 13: GPC chromatograph of mPEG350PCL.	19
SI Figure 14: GPC chromatograph of mPEG550PCL.	20
SI Figure 15: GPC chromatograph of mPEG750PCL.	21
SI Figure 16: GPC chromatograph of mPEG2000PCL.	22
SI Figure 17: ATR IR spectra of the polymers. ATR-IR: ν (cm ⁻¹) 3447, 2937, 2889, 2866, 1718, 1473, 1418, 1395, 1366, 1288, 1234, 1171, 1107, 1065, 1047, 957, 935, 733. 23	23
SI Figure 18: DSC of mPEG350PCL.	23
SI Figure 19: DSC of mPEG550PCL.	24
SI Figure 20: DSC of mPEG750PCL.	24
SI Figure 21: DSC of mPEG2000PCL.	24
SI Figure 22: Contact angle measurements of the 4 diblock copolymers for the assessment of their wettability properties. Error bars correspond to the standard deviation calculated from four measurements. The θ° values decrease with the increase of the hydrophilic block reflecting the increased hydrophilicity of the polymers.....	25
SI Figure 23: Analysis of ΔH measurements from DSC revealed a decrease in the percentage of crystallinity of the PCL block of the copolymers with an increase of the length of the hydrophilic block.	25
SI Figure 24: Reproducibility of the interfacial deposition method; Overlay of size measurements (DLS) of 4 batches of polymer NPs formed with PEG350PCL at a 0.1 mg polymer amount.	27
SI Figure 25: Zeta potential of the polymeric NPs. Key refers to PEG chain length of polymer.	27
SI Figure 26: Stability of the PEG350PCL polymeric NPs (final polymer concentration in water 0.2 mg/ml): The original measurement is in red, the same sample after 1 month in green and the blue is after sonication of the latter for 5 minutes. The size distribution is the same in all 3 cases.....	28
SI Figure 27: TEM image of mPEG350- PCL 2000 polymeric NPs at 0.05 mg/ml initial concentration in acetone (polymer amount 1mg). Diameters of selected NP indicated. Scale bar 1000 nm.	28
SI Figure 28: DSC of indomethacin as received	29
SI Figure 29: Size distribution of Indomethacin in water (1mg/ml), just after sonication, by DLS.	29
SI Figure 30: Polarised optical microscopy images of indomethacin in aqueous phase prior to the coating experiments. (a) without and (b) with the polariser. Indomethacin is clearly crystalline. Magnification 10x.	30
SI Figure 31: mPEG350-PCL2000 coated indomethacin nanoparticle size distribution by DLS. (polymer amount 0.1mg).....	31

SI Figure 32: Overlay of two experiments with mPEG350-PCL2000 and mPEG350-PCL2000 coated indomethacin nanoparticles (0.1mg polymer amount) to demonstrate the difference between the populations: Red line corresponds to the polymeric NPs that are formed in the absence of indomethacin, while the green distribution relates to the polymer-coated indomethacin 31

SI Figure 33: Centrifugation of the polymer coated drug nanoparticles (bottom graph) gives a PDI of 0.116, compared to a PDI that ranged from 0.394-0.265 in the pre-centrifugation suspensions (top graph)..... 32

SI Figure 34: Polarised optical microscopy images of the mPEG350PCL-coated indomethacin NPs. (a1) and (a2) prior to centrifugation, where uncoated drug particles form aggregates and (b1), (b2) after the purification where no crystals were observed (Magnification 10x). 33

SI Figure 35: TEM picture of mPEG-PCL coated indomethacin particles, (highest polymer starting concentration). Scale bar 200nm. 34

SI Figure 36: Reproducibility of the coating method; Overlay of 5 batches of mPEG350PCL-coated indomethacin NPs (0.1 mg polymer amount, 1 mg/ml indomethacin concentration in water)..... 34

SI Figure 37: Stability of the produced polymer coated-drug NPs; Same batch of mPEG350PCL-coated indomethacin NPs (0.1 mg polymer amount, 1 mg/ml indomethacin concentration in water) measured after 10 days. 35

SI Figure 38: Analysis of the effect of decreasing indomethacin concentration in the starting drug-bearing aqueous phase. Y-axis:Size distribution (Intensity), Right Y-axis PDI of measurements. 35

Molecular Dynamics Section

Topologies and parameters for MD

Acetone


```
;-----TITLE -----
;  acetone
;
; This file was generated at 01:26 on 2014-09-24 by
;
;           Automatic Topology Builder
;
;           REVISION 2014-09-22
;-----
; Authors      : Alpeshkumar K. Malde, Le Zuo, Matthew Breeze, Martin Stroet, Alan
E. Mark
;
; Institute    : Molecular Dynamics group,
;               School of Chemistry and Molecular Biosciences (SCMB),
;               The University of Queensland, QLD 4072, Australia
; URL         : http://compbio.biosci.uq.edu.au/atb
; Citation     : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, Oostenbrink
C, Mark AE.
;               An Automated force field Topology Builder (ATB) and repository:
version 1.0.
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037.
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m
;
; Disclaimer   :
;               While every effort has been made to ensure the accuracy and validity of
parameters provided below
;               the assignment of parameters is being based on an automated procedure
combining data provided by a
;               given user as well as calculations performed using third party software.
They are provided as a guide.
;               The authors of the ATB cannot guarantee that the parameters are complete or
that the parameters provided
;               are appropriate for use in any specific application. Users are advised to
treat these parameters with discretion
;               and to perform additional validation tests for their specific application
if required. Neither the authors
;               of the ATB or The University of Queensland except any responsibly for how
the parameters may be used.
;
; Release notes and warnings:
; (1) The topology is based on a set of atomic coordinates and other data
provided by the user after
;       after quantum mechanical optimization of the structure using different
levels of theory depending on
;       the nature of the molecule.
; (2) In some cases the automatic bond, bond angle and dihedral type assignment
is ambiguous.
;       In these cases alternative type codes are provided at the end of the line.
; (3) While bonded parameters are taken where possible from the nominated force
field non-standard bond, angle and dihedral
;       type code may be incorporated in cases where an exact match could not be
found. These are marked as "non-standard"
;       or "uncertain" in comments.
```

```

; (4) In some cases it is not possible to assign an appropriate parameter
automatically. "%" is used as a place holder
;     for those fields that could not be determined automatically. The parameters
in these fields must be assigned manually
;     before the file can be used.
;-----
; Input Structure : UAC
; Output          : UNITED ATOM topology
;     Use in conjunction with the corresponding united atom PDB file.
;-----
; Final Topology Generation was performed using:
; A B3LYP/6-31G* optimized geometry.
; Bonded and van der Waals parameters were taken from the GROMOS 53A6 parameter
set.
; Initial charges were estimated using the ESP method of Merz-Kollman.
; Final charges and charge groups were generated by method described in the ATB
paper.
; If required, additional bonded parameters were generated from a Hessian matrix
calculated at the B3LYP/6-31G* level of theory.
;
;     Topology file generated at 01:09 on 24 Sep 2014 for molecule
;     acetone (IUPAC: propan-2-one, database identifier: UAC)
;     by Automatic Topology Builder(revision 2014-09-22).
;
[ moleculetype ]
; Name      nrexcl
UAC        3
[ atoms ]
; nr  type  resnr  resid  atom  cgnr  charge  mass  total_charge
;   1  CH3   1     UAC   C3    1    -0.083  15.0350
;   2   C    1     UAC   C2    1     0.734  12.0110
;   3   O    1     UAC   O1    1    -0.568  15.9994      ; 0.083
;   4  CH3   1     UAC   C1    2    -0.083  15.0350      ; -0.083
; total charge of the molecule: 0.000
[ bonds ]
; ai  aj  funct  c0      c1
;   1  2   2    0.1520  5.4300e+06
;   2  3   2    0.1230  1.6600e+07
;   2  4   2    0.1520  5.4300e+06
[ pairs ]
; ai  aj  funct ; all 1-4 pairs but the ones excluded in GROMOS itp
[ angles ]
; ai  aj  ak  funct  angle  fc
;   1  2  3   2    125.00  750.00
;   1  2  4   2    120.00  560.00
;   3  2  4   2    125.00  750.00
[ dihedrals ]
; GROMOS improper dihedrals
; ai  aj  ak  al  funct  angle  fc
;   2  1  3  4   2     0.00  167.36
[ dihedrals ]
; ai  aj  ak  al  funct  ph0    cp    mult
[ exclusions ]
; ai  aj  funct ; GROMOS 1-4 exclusions

```

Polymer residual topologies



```
[ bondedtypes ]
; bonds  angles  dihedrals  impropers
      2      2          1          2

[ pgs ]
[ atoms ]
;      name      type      charge  chargegroup
      C1         CH3       0.260   1
      OX         OE        -0.260   1

[ bonds ]
;      ai      aj      gromos type
      C1      OX      gb_18   ;0.1430  8.1800e+06
      OX      +C1     gb_18   ;0.1430  8.1800e+06

[ angles ]
;      ai      aj      ak      gromos type
      C1      OX      +C1     118.00   1080.00   ;109.50   320.00
      OX      +C1     +C2     ga_15

[ dihedrals ]
;      ai      aj      ak      a1      gromos type
      C1      OX      +C1     +C2     gd_23
      OX      +C1     +C2     +OX     gd_23

;The following is the REPEAT PEG part
;consists of -[CH2-CH2-O]-

[ pgr ]
[ atoms ]
;      name      type      charge  chargegroup
      C1         CH2       0.171   1
      C2         CH2       0.118   1
      OX         OE        -0.289   2

[ bonds ]
;      ai      aj      gromos type
      C1      C2      gb_27   ;0.1530  7.1500e+06
      C2      OX      gb_18
      OX      +C1     gb_18   ;for any of the next peg units

[ angles ]
;      ai      aj      ak      gromos type
      C1      C2      OX      ga_15           ;repeat unit
      C2      OX      +C1     118.00         1080.00       ;for the
repeat and the 1st CL unit
      OX      +C1     +C2     ga_15           ; for the repeat

[ dihedrals ]
```

```

;      ai      aj      ak      al      gromos type
      C1      C2      OX      +C1      gd_23      ;for the next PEG and the 1st
PCL
      C2      OX      +C1      +C2      gd_23      ;for the next PEG
      OX      +C1      +C2      +OX      gd_23      ;for the PEG repeat CHANGED
IT FROM 37
      OX      +C1      +C2      +C3      gd_23      ;for the CL

```

[pge] ; we need this connecting site because the bonds and dihedrals in the connection oxygen carbons are different from those on mpeg

```

[ atoms ]
;      name      type      charge      chargegroup
      C1      CH2      0.186      1
      C2      CH2      0.102      1
      OX      OE      -0.288      2

```

```

[ bonds ]
;      ai      aj      gromos type
      C1      C2      gb_27      ;0.1530  7.1500e+06
      C2      OX      gb_18
      OX      +C1      gb_5      ;for the CLs that is coming after

```

```

[ angles ]
;      ai      aj      ak      gromos type
      C1      C2      OX      ga_15      ; 111.00 530
      C2      OX      +C1      118.00      1080.00
      OX      +C1      +C2      ga_19
      OX      +C1      +OC      ga_33

```

```

[ dihedrals ]
;      ai      aj      ak      al      gromos type
      C1      C2      OX      +C1      gd_12
      C2      OX      +C1      +C2      gd_13
      C2      OX      +C1      +OC      gd_12      ;for the CL carbonyl dihedral
      OX      +C1      +C2      +OC      gd_12      ;
      OX      +C1      +C2      +C3      gd_12

```

```

[ impropers ]
      OX      +C1      +OC      +C2      gi_1      ;0.00  167.36      ;for the
connection with the CL unit

```

;Caprolactone connecting unit

```

[ pcs ]
[ atoms ]
;      name      type      charge      chargegroup
      C1      C      0.226      1
      OC      O      -0.352      1
      C2      CH2      0.085      1
      C3      CH2      0.041      2
      C4      CH2      0.000      2
      C5      CH2      0.028      3
      C6      CH2      0.254      3
      OX      OA      -0.282      3

```

```

[ bonds ]
;      ai      aj      gromos type
      C1      OC      gb_5
      C1      C2      gb_27
      C2      C3      gb_27
      C3      C4      gb_27
      C4      C5      gb_27

```

```

C5      C6      gb_27
C6      OX      gb_18
OX      +C1     gb_18      ;for the repeat residue

[ angles ]
;      ai      aj      ak      gromos type
OC     C1      C2      ga_30      ;121.00      685.00
C1     C2      C3      ga_15      ;111.00      530.00
C2     C3      C4      ga_15
C3     C4      C5      ga_15
C4     C5      C6      ga_15
C5     C6      OX      ga_13      ;109.50      520.00
C6     OX      +C1     118.00      1080.00
OX     +C1     +C2     ga_30
OX     +C1     +OC     ga_33

[ dihedrals ]
;      ai      aj      ak      al      gromos type
OC     C1      C2      C3      gd_12      ;
C1     C2      C3      C4      gd_29      ;0.00      3.77      3
C2     C3      C4      C5      gd_29      ;0.00      3.77      3
C3     C4      C5      C6      gd_29      ;0.00      3.77      3
C4     C5      C6      OX      gd_23      ;
C5     C6      OX      +C1     gd_12      ;
C6     OX      +C1     +C2     gd_13      ;for the repeat residue
C6     OX      +C1     +OC     gd_12      ;repeat residue
OX     +C1     +C2     +C3     gd_12      ;repeat residue

[ impropers ]
OX     +C1     +OC     +C2     gi_1      ;0.00      167.36

; CAPROLACTONE UNITED atom
; Constructed by Ioanna

;The following is the c1 monomer residue
;consists of -[O=C-CH2-CH2-CH2-CH2-CH2-0]
[ p1 ]
[ atoms ]
;      name      type      charge      chargegroup
C1     C          0.271      1
OC     O          -0.352     1
C2     CH2        0.081      1
C3     CH2        -0.013     2
C4     CH2        0.013      2
C5     CH2        0.027      3
C6     CH2        0.255      3
OX     OA         -0.282     3

[ bonds ]
;      ai      aj      gromos type
C1     OC      gb_5
C1     C2      gb_27
C2     C3      gb_27
C3     C4      gb_27
C4     C5      gb_27
C5     C6      gb_27
C6     OX      gb_18
OX     +C1     gb_18      ;for the repeat residue

[ angles ]

```

```

;      ai      aj      ak      gromos type
      OC      C1      C2      ga_30      ;121.00      685.00
      C1      C2      C3      ga_15      ;111.00      530.00
      C2      C3      C4      ga_15
      C3      C4      C5      ga_15
      C4      C5      C6      ga_15
      C5      C6      OX      ga_13      ;109.50      520.00
      C6      OX      +C1     118.00      1080.00
      OX      +C1     +C2     ga_30
      OX      +C1     +OC     ga_33

[ dihedrals ]
;      ai      aj      ak      al      gromos type
      OC      C1      C2      C3      gd_12      ;
      C1      C2      C3      C4      gd_29      ;0.00      3.77      3
      C2      C3      C4      C5      gd_29      ;0.00      3.77      3
      C3      C4      C5      C6      gd_29      ;0.00      3.77      3
      C4      C5      C6      OX      gd_23      ;
      C5      C6      OX      +C1     gd_12      ;
      C6      OX      +C1     +C2     gd_13      ;for the repeat residue
      C6      OX      +C1     +OC     gd_12      ;repeat residue
      OX      +C1     +C2     +C3     gd_12      ;repeat residue

[ impropers ]
      OX      +C1     +OC     +C2     gi_1      ;0.00      167.36

[ pce]
[ atoms ]
;      name     type     charge  chargegroup
      C1      C      0.234   1
      OC      O      -0.353  1
      C2      CH2     0.078   1
      C3      CH2     0.041   1
      C4      CH2     0.000   2
      C5      CH2     0.033   2
      C6      CH2     0.100   3
      OX      OA      -0.328  3
      HA      H       0.195   3

[ bonds ]
;      ai      aj      gromos type
      C1      OC      gb_5
      C1      C2      gb_27
      C2      C3      gb_27
      C3      C4      gb_27
      C4      C5      gb_27
      C5      C6      gb_27
      C6      OX      gb_18
      OX      HA      gb_1

[ angles ]
;      ai      aj      ak      gromos type
      OC      C1      C2      ga_30      ;121.00      685.00
      C1      C2      C3      ga_15      ;111.00      530.00
      C2      C3      C4      ga_15
      C3      C4      C5      ga_15
      C4      C5      C6      ga_15
      C5      C6      OX      ga_13      ;109.50      520.00
      C6      OX      HA      118.00      1080.00

```


```

[ dihedrals ]
;      ai      aj      ak      al      gromos type
      OC      C1      C2      C3      gd_12      ;
      C1      C2      C3      C4      gd_29      ;0.00      3.77      3
      C2      C3      C4      C5      gd_29      ;0.00      3.77      3
      C3      C4      C5      C6      gd_29      ;0.00      3.77      3
      C4      C5      C6      OX      gd_23      ;
      C5      C6      OX      HA      gd_30      ;

;      H1      N1      C1      C2
      N1      C1      O1      C2      2      0.00      167.36
;
;      N1      C1      C2      H2
;
;      C1      C2      H2      +N1
;
;      C1      C2      H2      C3
;
;      C1      C2      C3      C4
;
;      C1      C2      +N1      +C1
;
;      C2      H2      C3      C4
      C2      C3      C4      C5      1      0.00      5.92      3
;
;      C2      H2      +N1      +H1
;
;      C2      H2      +N1      +C1
;
;      C2      +N1      +H1      +C1
      C2      +N1      +C1      +O1      1      180.00      33.50      2
;
;      C2      +N1      +C1      +C2
      C3      C4      C5      O2      1      180.00      1.00      6
;
;      C3      C4      C5      O3
;
;      C4      C5      O3      H3
      O2      C5      O3      H3      1      180.00      7.11      2


```

Control Simulation: mPEG350-PCL2000 in acetone




SI Figure 1: Five mPEG350-PCL2000 polymer chains surrounded by acetone (not shown), a favourable solvent. Periodic boundary conditions (PBC) apply, where the molecules can move across the end of the box.

Control Simulation: mPEG350-PCL2000 in water




SI Figure 2: Five mPEG350-PCL2000 polymer chains surrounded by water (not shown). The polymers self aggregate within 4ns and then they form a larger polymeric NP within the first 32 ns of the simulation. PBC apply.

Control Simulation: Indomethacin NP in acetone




SI Figure 3: A 5nm diameter indomethacin NP surrounded by acetone (not shown), a favourable solvent. The NP dissolves. PBC apply.

Control Simulation: Indomethacin NP in water




SI Figure 4: A 5nm diameter indomethacin NP surrounded by water (not shown). The NP stays intact. PBC apply.

Control Simulation: Formation of polymeric NP in interfacial deposition




SI Figure 5: *m*PEG350 (light blue)-*b*-PCL2000 (dark blue) polymer chains in the phase 1 of the interfacial deposition simulation, for the formation of a polymer NP. Snapshots taken at every 20 ns, solvents not shown for clarity. The polymer chains start to aggregate,




SI Figure 6: *m*PEG350 (light blue)-*b*-PCL2000 (dark blue) polymer chains in the phase 2 of the interfacial deposition simulation, for the formation of a polymer NP. Snapshots taken at the end of every 10 ns MD run where acetone molecules (pink) are replaced by water molecules.

Control Simulation: Indomethacin NP in interfacial deposition




SI Figure 7: Control simulation of the indomethacin NP (grey) to evaluate the NP's stability in the biphasic system. The drug NP stays intact until 70 ns, however as the presence acetone (pink) in the NP's surrounding environment increases, the NP starts to swell up.


Main Simulation: Interfacial Deposition of mPEG350-PCL2000




SI Figure 8: Phase 1 of the interfacial deposition simulation of mPEG350 (light blue)-b-PCL2000 (dark blue) polymer chains in the presence of a 5 nm indomethacin NP (grey). Solvent molecules are not shown for clarity. PBC apply. Snapshots taken at various time points of the simulation. The polymer chains start to aggregate slowly as the acetone diffuses towards the water region. The indomethacin NP stays intact in the aqueous region until it reaches close proximity with the polymer chains and gets dissolved at 108 ns.



SI Figure 9: Phase 2 of the interfacial deposition for the formation of a polymer-coated drug NP. Snapshots taken at the end of every 10 ns MD run where acetone molecules (pink) are replaced by water molecules, mimicking evaporation of the acetone. A polymer-drug NP of 7nm in diameter is formed. Water is not shown for clarity, PBC conditions apply.




SI Figure 10: Number of contacts and the distance between the PCL blocks and the indomethacin molecules during phase 1 of the interfacial deposition.



SI Figure 11: Radius of gyration (a, c) and end-to-end distances (b, d) for both phases 1 and 2 of the polymer-drug NP formation simulation. c and d refer just to phase 2.

Experimental Section

Polymer Characterisation: NMR



SI Figure 12: NMR Spectra of the synthesised polymers. PEG350PCL: ¹H NMR (figure 4.1) (400 MHz, CDCl₃, ppm): 1.41 (m, 34, CH₂CH₂CH₂), 1.68 (m, 68, CH₂CH₂CH₂), 2.33 (t, 34, COCH₂), 3.40 (s, 3, PEGCH₃), 3.67 (m, 24, OCH₂CH₂O), 4.08 (t, 34, CH₂CH₂CH₂O), 4.25 (t, 2, CH₂CH₂OCO).

Polymer Characterisation: GPC

Sample: IDSA09

Date: 24/04/2015 17:32:03

Workbook: CHCl3_conv_150420.plw

Inj File: 150424-0006.cgm

Path: C:\Cirrus Workbooks\2015\CHCl3_conv_150420\CHCl3_conv_150420.plw


Res. File: 150424-0006.rst

Method: PSeasy_CHCl3_150420


Batch: 150424

Eluent: Chloroform

Chromatogram



Distribution Plots



Peak No	Mp	Mn	Mw	Mz	Mz+1	Mv	PD
1	9447	7384	11839	17751	24269	11081	1.60333

SI Figure 13: GPC chromatograph of mPEG350PCL.

Sample:IDSB10

Date:24/04/2015 15:44:17

Workbook: CHCl3_conv_150420.plw

Inj File: 150424-0003.cgrm



Path: C:\Cirrus Workbooks\2015\CHCl3_conv_150420\CHCl3_conv_150420.plw

Res. File: 150424-0003-Repeat (01).rst

Method: PSeasy_CHCl3_150420

Batch: 150424

Eluent: Chloroform



Peak No	Mp	Mn	Mw	Mz	Mz+1	Mv	PD
1	8790	6823	10966	17114	24611	10219	1.60721

SI Figure 14: GPC chromatograph of mPEG550PCL.

Sample:IDSC11

Date:24/04/2015 16:56:13

Workbook: CHCl3_conv_150420.plw

Inj File: 150424-0005.cgrm

Path: C:\Cirrus Workbooks\2015\CHCl3_conv_150420\CHCl3_conv_150420.plw


Res. File: 150424-0005-Repeat (01).rst

Method: PSeasy_CHCl3_150420


Batch: 150424

Eluent: Chloroform

Chromatogram



Distribution Plots



Peak No	Mp	Mn	Mw	Mz	Mz+1	Mv	PD
1	8678	7601	10911	15380	20763	10345	1.43547

SI Figure 15: GPC chromatograph of mPEG750PCL.

Sample:IDSF16

Date:24/04/2015 15:08:27

Workbook: CHCl3_conv_150420.plw

Inj File: 150424-0002.cgrm

Path: C:\Cirrus Workbooks\2015\CHCl3_conv_150420\CHCl3_conv_150420.plw


Res. File: 150424-0002-Repeat (01).rst

Method: PSeasy_CHCl3_150420


Batch: 150424

Eluent: Chloroform

Chromatogram




Distribution Plots



Peak No	Mp	Mn	Mw	Mz	Mz+1	Mv	PD
1	11268	10957	16353	23604	32805	15456	1.49247


SI Figure 16: GPC chromatograph of mPEG2000PCL.

Polymer Characterisation: ATR-IR




SI Figure 17: ATR IR spectra of the polymers. ATR-IR: ν (cm⁻¹) 3447, 2937, 2889, 2866, 1718, 1473, 1418, 1395, 1366, 1288, 1234, 1171, 1107, 1065, 1047, 957, 935, 733.


Polymer Characterisation: DSC




SI Figure 18: DSC of mPEG350PCL.



SI Figure 19: DSC of mPEG550PCL.




SI Figure 20: DSC of mPEG750PCL.




SI Figure 21: DSC of mPEG2000PCL.

Polymer Characterisation: Contact Angle



SI Figure 22: Contact angle measurements of the 4 diblock copolymers for the assessment of their wettability properties. Error bars correspond to the standard deviation calculated from four measurements. The θ° values decrease with the increase of the hydrophilic block reflecting the increased hydrophilicity of the polymers.

Polymer Characterisation: DSC




SI Figure 23: Analysis of ΔH measurements from DSC revealed a decrease in the percentage of crystallinity of the PCL block of the copolymers with an increase of the length of the hydrophilic block.

The contribution of the mPEG chain in the ΔH of the copolymers was calculated by:

$\Delta H_{mPEG} = \Delta H * \left(\frac{w}{w} \% (mPEG) \right) = \Delta H * \frac{MW_{mPEG}}{114.14 * DP_{PCL} + MW_{mPEG}}$ where DP_{PCL} is the number of CL units in the PCL blocks as calculated via H^1 NMR. Then $\Delta H_{HPCL} = \Delta H - \Delta H_{mPEG}$.


Polymeric NP Characterisation: DLS

PEG350PCL Polymeric NPs different batches (polymer amount 0.1mg)




SI Figure 24: Reproducibility of the interfacial deposition method; Overlay of size measurements (DLS) of 4 batches of polymer NPs formed with PEG350PCL at a 0.1 mg polymer amount.

Polymeric NP Characterisation: ζ -potential




SI Figure 25: Zeta potential of the polymeric NPs. Key refers to PEG chain length of polymer.




SI Figure 26: Stability of the PEG350PCL polymeric NPs (final polymer concentration in water 0.2 mg/ml): The original measurement is in red, the same sample after 1 month in green and the blue is after sonication of the latter for 5 minutes. The size distribution is the same in all 3 cases.

Polymeric NP Characterisation TEM



SI Figure 27: TEM image of mPEG350- PCL 2000 polymeric NPs at 0.05 mg/ml initial concentration in acetone (polymer amount 1mg). Diameters of selected NP indicated. Scale bar 1000 nm.


Indomethacin bulk characterisation: DSC



SI Figure 28: DSC of indomethacin as received



Indomethacin NP Characterisation: DLS

	Size (d.nm):	% Intensity:	St Dev (d.nm):
Z-Average (d.nm): 687.2	Peak 1: 712.2	96.1	357.0
PdI: 0.377	Peak 2: 5199	3.9	526.2
Intercept: 0.836	Peak 3: 0.000	0.0	0.000
Result quality : Good			



SI Figure 29: Size distribution of Indomethacin in water (1mg/ml), just after sonication, by DLS.


Indomethacin NP Characterisation: POM




SI Figure 30: Polarised optical microscopy images of indomethacin in aqueous phase prior to the coating experiments. (a) without and (b) with the polariser. Indomethacin is clearly crystalline. Magnification 10x.

Polymer-coated indomethacin NP Characterisation: DLS

	Size (d.nm):	% Intensity:	St Dev (d.nm):
Z-Average (d.nm): 217.3	Peak 1: 252.1	100.0	103.7
Pdl: 0.141	Peak 2: 0.000	0.0	0.000
Intercept: 0.919	Peak 3: 0.000	0.0	0.000
Result quality : Good			




SI Figure 31: mPEG350-PCL2000 coated indomethacin nanoparticle size distribution by DLS. (polymer amount 0.1mg)




SI Figure 32: Overlay of two experiments with mPEG350-PCL2000 and mPEG350-PCL2000 coated indomethacin nanoparticles (0.1mg polymer amount) to demonstrate the difference between the populations: Red line corresponds to the polymeric NPs that are formed in the absence of indomethacin, while the green distribution relates to the polymer-coated indomethacin

	Size (d.nm):	% Intensity:	St Dev (d.nm):
Z-Average (d.nm): 308.0	Peak 1: 265.5	96.5	64.89
Pdl: 0.324	Peak 2: 5319	3.5	402.5
Intercept: 0.906	Peak 3: 0.000	0.0	0.000
Result quality : Good			




	Size (d.nm):	% Intensity:	St Dev (d.nm):
Z-Average (d.nm): 240.0	Peak 1: 260.5	100.0	77.99
Pdl: 0.116	Peak 2: 0.000	0.0	0.000
Intercept: 0.916	Peak 3: 0.000	0.0	0.000
Result quality : Good			




SI Figure 33: Centrifugation of the polymer coated drug nanoparticles (bottom graph) gives a PDI of 0.116, compared to a PDI that ranged from 0.394-0.265 in the pre-centrifugation suspensions (top graph)

Polymer-coated indomethacin NP Characterisation: POM




SI Figure 34: Polarised optical microscopy images of the mPEG350PCL-coated indomethacin NPs. (a1) and (a2) prior to centrifugation, where uncoated drug particles form aggregates and (b1), (b2) after the purification where no crystals were observed (Magnification 10x).

Polymer-coated indomethacin NP Characterisation: TEM




SI Figure 35: TEM picture of mPEG-PCL coated indomethacin particles, (highest polymer starting concentration). Scale bar 200nm.

Polymer-coated indomethacin NP Characterisation: Reproducibility




SI Figure 36: Reproducibility of the coating method; Overlay of 5 batches of mPEG350PCL-coated indomethacin NPs (0.1 mg polymer amount, 1 mg/ml indomethacin concentration in water)

Polymer-coated indomethacin NP Characterisation: Stability



SI Figure 37: Stability of the produced polymer coated-drug NPs; Same batch of mPEG350PCL-coated indomethacin NPs (0.1 mg polymer amount, 1 mg/ml indomethacin concentration in water) measured after 10 days.

Polymer-coated indomethacin NP Characterisation: Effect of Drug amount



SI Figure 38: Analysis of the effect of decreasing indomethacin concentration in the starting drug-bearing aqueous phase. Y-axis: Size distribution (Intensity), Right Y-axis PDI of measurements.

Polymer-coated indomethacin NP Characterisation: Drug Loading

Table 1 - Calculation of drug loading and encapsulation efficiency via UV-Vis, after lyophilisation of the suspension

mPEG350PCL amount (mg/ml)	Starting Drug amount (mg)	% Drug loading	Entrapment efficiency (eq. 2)	Entrapment efficiency ‡ (amended eq. 2)
1	1	13.79	16.0	95.53
0.5	1	23.17	15.32	91.47
0.1	1	64.39	18.41	-
0.05	1	78.27	18.31	99.02

% Drug loading = polymer amount/ (polymer amount + drug amount in nanoparticles) *100
(Assuming all polymer is still present in drug coated nanoparticles)

In order to account for the drug loss during the loading of the aqueous bearing syringe and the pumping, Ep2 was amended into the following:

%Entrapment Efficiency ‡

= (amount of coated drug/amount of recovered control drug NPs)*100.